Lovenox (enoxaparin)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

Deep Vein Thrombosis (DVT)

What brand names are available for enoxaparin?

Lovenox

Is enoxaparin available as a generic drug?

GENERIC AVAILABLE: Yes

Do I need a prescription for enoxaparin?

Yes

What are the uses for enoxaparin?

What are the side effects of enoxaparin?

Common side effect associated with Lovenox are:

Other possible side effects include:

  • Abnormal liver tests in the blood
  • Mild local irritation
  • pain
  • Local injection site reaction

Possible serious side effects include:

Quick GuideDVT in Pictures: Symptoms of Deep Vein Thrombosis, Beyond Leg Pain and More

DVT in Pictures: Symptoms of Deep Vein Thrombosis, Beyond Leg Pain and More

What is the dosage for enoxaparin?

Lovenox is administered by injection under the skin (subcutaneous) or intravenously.

  • Preventing deep vein thrombosis after abdominal surgery: 40 mg subcutaneous injection once daily.
  • Preventing deep vein thrombosis after knee replacement: 30 mg subcutaneous injection every 12 hours.
  • Preventing deep vein thrombosis after hip replacement: 30 mg every 12 hours or 40 mg once daily by subcutaneous injection.
  • Preventing deep vein thrombosis in ill patients with limited mobility: 40 mg subcutaneous injection once daily.
  • Treatment of deep vein thrombosis or pulmonary embolism: 1 mg/kg every 12 hours or 1.5 mg/kg once daily by subcutaneous injection.
  • Outpatient treatment of deep vein thrombosis: 1 mg/kg subcutaneous injection every 12 hours.
  • Treatment of severe heart attacks (ST elevation myocardial infarction or STEMI): For patients under the age of 75, 30 mg intravenously plus 1 mg/kg subcutaneously followed by 1 mg/kg every 12 hours (maximum of 100 mg for each of the first two subcutaneous doses only). For patients over age 75, 0.75 mg/kg subcutaneously every 12 hours (maximum of 75 mg for each of the first two subcutaneous doses only). All patients should receive aspirin. Doses should be reduced in patients with impaired kidney function.
  • Treatment of chest pain (unstable angina) or mild heart attack (non-Q-wave myocardial infarction): 1 mg/kg subcutaneously every 12 hours with aspirin.
  • For coronary artery stent procedures (percutaneous coronary intervention or PCI): Patients should receive 0.3 mg/kg during stent placement if the last dose of Lovenox was administered more than 8 hours before the procedure.

Which drugs or supplements interact with enoxaparin?

  • Medications that increase the risk of bleeding will add to the effects of Lovenox and further increase the risk of bleeding that is associated with Lovenox. Such medications include aspirin, clopidogrel (Plavix), warfarin (Coumadin), other anticoagulants, and nonsteroidal anti-inflammatory drugs such as ibuprofen (Motrin; Advil), naproxen (Naprosyn), diclofenac (Voltaren), and others.

Is enoxaparin safe to take if I'm pregnant or breastfeeding?

  • Lovenox does not cross the placenta and shows no evidence of effects on the fetus. It often is used during pregnancy as an alternative to oral anticoagulants such as warfarin (Coumadin), which cannot be safely used during pregnancy.
  • Lovenox multiple-dose vials contain benzyl alcohol as a preservative. Benzyl alcohol has been associated with a fatal "gasping syndrome" in premature neonates. Lovenox vials preserved with benzyl alcohol should be used with caution in pregnant women and only if clearly needed because benzyl alcohol may cross the placenta.
  • It is not known if Lovenox is excreted in breast milk. Since most medicines are excreted in breast milk, it is recommended that women receiving Lovenox should not breastfeed.

What else should I know about enoxaparin?

What preparations of enoxaparin are available?

  • Lovenox is available in pre-filled syringes containing 30, 40, 60, 80, 100, 120, and 150 mg.
  • Multiple dose vial: 300 mg

How should I keep enoxaparin stored?

All Lovenox products should be stored at room temperature, between 15 and 30 C (59 and 86 F).

Reference: FDA Prescribing Information

Quick GuideDVT in Pictures: Symptoms of Deep Vein Thrombosis, Beyond Leg Pain and More

DVT in Pictures: Symptoms of Deep Vein Thrombosis, Beyond Leg Pain and More

Summary

Lovenox (enoxaparin) is a medication prescribed for preventing deep vein thrombosis (DVT) and pulmonary embolism after surgeries such as abdominal, hip or knee replacement, and in patients with reduced mobility due to illness. Lovenox is also prescribed to prevent a second heart attack and related complications after a heart attack, and for preventing blood clots in arterial stents. Side effects include

  • Fluid retention
  • Nausea
  • Bleeding
  • Local injection site reaction
  • Mild local irritation
  • Fever

Drug interactions, dosing, and pregnancy and breastfeeding safety information should be reviewed prior to taking this medication.

Treatment & Diagnosis

Medications & Supplements

Prevention & Wellness

Subscribe to MedicineNet's Heart Health Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

See more info: enoxaparin on RxList
Reviewed on 9/16/2016
References
Reference: FDA Prescribing Information

Health Solutions From Our Sponsors